Literature DB >> 23782159

A mechanism-driven treatment for chronic lymphocytic leukemia?

Robin Foà, Anna Guarini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23782159     DOI： 10.1056/NEJMe1303054

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Lodovico Terzi-di-Bergamo; Lorenzo De Paoli; Michaela Cerri; Guido Ghilardi; Annalisa Chiarenza; Pietro Bulian; Carlo Visco; Francesca R Mauro; Fortunato Morabito; Agostino Cortelezzi; Francesco Zaja; Francesco Forconi; Luca Laurenti; Ilaria Del Giudice; Massimo Gentile; Iolanda Vincelli; Marina Motta; Marta Coscia; Gian Matteo Rigolin; Alessandra Tedeschi; Antonino Neri; Roberto Marasca; Omar Perbellini; Carol Moreno; Giovanni Del Poeta; Massimo Massaia; Pier Luigi Zinzani; Marco Montillo; Antonio Cuneo; Valter Gattei; Robin Foà; Gianluca Gaidano
Journal:  Blood       Date:  2015-08-14       Impact factor: 22.113

2.  Ibrutinib in the real world patient: many lights and some shades.

Authors:  Paolo Ghia; Antonio Cuneo
Journal:  Haematologica       Date:  2016-12       Impact factor: 9.941

3.  A role for oleoylethanolamide in chronic lymphocytic leukemia.

Authors:  M Masoodi; E Lee; M Eiden; A Bahlo; Y Shi; R B Ceddia; C Baccei; P Prasit; D E Spaner
Journal:  Leukemia       Date:  2014-01-13       Impact factor: 11.528

Review 4.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

5.  A Selective Novel Peroxisome Proliferator-Activated Receptor (PPAR)-α Antagonist Induces Apoptosis and Inhibits Proliferation of CLL Cells In Vitro and In Vivo.

Authors:  Davorka Messmer; Kymmy Lorrain; Karin Stebbins; Yalda Bravo; Nicholas Stock; Geraldine Cabrera; Lucia Correa; Austin Chen; Jason Jacintho; Nicholas Chiorazzi; Xiao Jie Yan; David Spaner; Peppi Prasit; Daniel Lorrain
Journal:  Mol Med       Date:  2015-06-09       Impact factor: 6.354

Review 6.  Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy.

Authors:  Sara Martinelli; Antonio Cuneo; Luca Formigaro; Maurizio Cavallari; Enrico Lista; Francesca Maria Quaglia; Maria Ciccone; Antonella Bardi; Eleonora Volta; Elisa Tammiso; Elena Saccenti; Olga Sofritti; Giulia Daghia; Massimo Negrini; Melissa Dabusti; Paolo Tomasi; Sabrina Moretti; Francesco Cavazzini; Gian Matteo Rigolin
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-15       Impact factor: 2.576

7.  Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Authors:  Antonio Cuneo; George Follows; Gian Matteo Rigolin; Alfonso Piciocchi; Alessandra Tedeschi; Livio Trentin; Angeles Medina Perez; Marta Coscia; Luca Laurenti; Gerardo Musuraca; Lucia Farina; Alfredo Rivas Delgado; Ester Maria Orlandi; Piero Galieni; Francesca Romana Mauro; Carlo Visco; Angela Amendola; Atto Billio; Roberto Marasca; Annalisa Chiarenza; Vittorio Meneghini; Fiorella Ilariucci; Monia Marchetti; Stefano Molica; Francesca Re; Gianluca Gaidano; Marcos Gonzalez; Francesco Forconi; Stefania Ciolli; Agostino Cortelezzi; Marco Montillo; Lukas Smolej; Anna Schuh; Toby A Eyre; Ben Kennedy; Kris M Bowles; Marco Vignetti; Javier de la Serna; Carol Moreno; Robin Foà; Paolo Ghia
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

8.  Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?

Authors:  Antonio Cuneo; Robin Foà
Journal:  Mediterr J Hematol Infect Dis       Date:  2019-03-01       Impact factor: 2.576

9.  Ibrutinib for B cell malignancies.

Authors:  Aileen Novero; Pavan M Ravella; Yamei Chen; George Dous; Delong Liu
Journal:  Exp Hematol Oncol       Date:  2014-01-28

10.  Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups.

Authors:  Antonio Cuneo; Francesco Cavazzini; Maria Ciccone; Giulia Daghia; Olga Sofritti; Elena Saccenti; Massimo Negrini; Gian Matteo Rigolin
Journal:  Cancer Med       Date:  2014-03-19       Impact factor: 4.452
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.